Peg-Grafted Liposomes for L-Asparaginase Encapsulation

被引:9
|
作者
Guimaraes, Marina de Souza [1 ]
Muso Cachumba, Jorge Javier [1 ]
Bueno, Cecilia Zorzi [1 ]
Torres-Obreque, Karin Mariana [1 ]
Ruiz Lara, Grace Veronica [1 ]
Monteiro, Gisele [1 ]
Souza Barbosa, Leandro Ramos [2 ,3 ]
Pessoa Jr, Adalberto [1 ]
Rangel-Yagui, Carlota de Oliveira [1 ]
机构
[1] Univ Sao Paulo, Sch Pharmaceut Sci, Dept Biochem & Pharmaceut Technol, BR-05508000 Sao Paulo, SP, Brazil
[2] Univ Sao Paulo, Inst Phys, Dept Gen Phys, BR-05508000 Sao Paulo, SP, Brazil
[3] Brazilian Ctr Res Energy & Mat CNPEM, Brazilian Synchrotron Light Lab LNLS, BR-13083100 Campinas, SP, Brazil
基金
巴西圣保罗研究基金会;
关键词
liposome; pegylated liposome; nanoreactor; nanocarrier; L-asparaginase; acute lymphoblastic leukemia; MEMBRANE-PERMEABILITY; ALPHA-TOCOPHEROL; VITAMIN-E; STABILITY; SIZE; PHOSPHOLIPIDS; NANOCARRIERS; POLYMERSOMES; DOXORUBICIN; EFFICIENCY;
D O I
10.3390/pharmaceutics14091819
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
L-asparaginase (ASNase) is an important biological drug used to treat Acute Lymphoblastic Leukemia (ALL). It catalyzes the hydrolysis of L-asparagine (Asn) in the bloodstream and, since ALL cells cannot synthesize Asn, protein synthesis is impaired leading to apoptosis. Despite its therapeutic importance, ASNase treatment is associated to side effects, mainly hypersensitivity and immunogenicity. Furthermore, degradation by plasma proteases and immunogenicity shortens the enzyme half-life. Encapsulation of ASNase in liposomes, nanostructures formed by the self-aggregation of phospholipids, is an attractive alternative to protect the enzyme from plasma proteases and enhance pharmacokinetics profile. In addition, PEGylation might prolong the in vivo circulation of liposomes owing to the spherical shielding conferred by the polyethylene (PEG) corona around the nanostructures. In this paper, ASNase was encapsulated in liposomal formulations composed by 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) or 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) containing or not different concentrations of 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N [methoxy (polyethylene glycol)-2000] (DSPE-PEG). Nanostructures of approximately 142-202 nm of diameter and polydispersity index (PDI) of 0.069 to 0.190 were obtained and the vesicular shape confirmed by Transmission Electron Microscopy (TEM and cryo-TEM). The encapsulation efficiency (%EE) varied from 10% to 16%. All formulations presented activity in contact with ASNase substrate, indicating the liposomes permeability to Asn and/or enzyme adsorption at the nanostructures' surface; the highest activity was observed for DMPC/DSPE-PEG 10%. Finally, we investigated the activity against the Molt 4 leukemic cell line and found a lower IC50 for the DMPC/DSPE-PEG 10% formulation in comparison to the free enzyme, indicating our system could provide in vivo activity while protecting the enzyme from immune system recognition and proteases degradation.
引用
收藏
页数:18
相关论文
共 50 条
  • [41] Aggregation phenomenon of PEG-grafted chitosan in aqueous solution
    Ouchi, T
    Nishizawa, H
    Ohya, Y
    POLYMER, 1998, 39 (21) : 5171 - 5175
  • [42] PEG-grafted PVA Membrane and Its Blood Compatibility
    JIN Gu*
    ChemicalResearchinChineseUniversities, 2011, 27 (06) : 1078 - 1082
  • [43] Preparation of PEG-grafted immunomagnetoliposomes and their application in cell sorting
    Domingo, JC
    Mercadal, M
    Petriz, J
    Garcia, J
    de Madariaga, MA
    CELLULAR & MOLECULAR BIOLOGY LETTERS, 1999, 4 (04) : 583 - 597
  • [44] INVIVO EFFECTS OF INTRAPERITONEALLY INJECTED L-ASPARAGINASE SOLUTION AND L-ASPARAGINASE IMMOBILIZED WITHIN SEMIPERMEABLE NYLON MICRCAPSULES WITH EMPHASIS ON BLOOD L-ASPARAGINASE, BODY L-ASPARAGINASE, AND PLASMA L-ASPARAGINE LEVELS
    CHONG, EDS
    CHANG, TMS
    ENZYME, 1974, 18 (3-4) : 218 - 239
  • [45] CLINICAL-PHARMACOLOGY OF POLYETHYLENE-GLYCOL L-ASPARAGINASE (PEG-L-ASE)
    HO, DHW
    BROWN, NS
    YEN, A
    HOLMES, R
    KEATING, M
    ABUCHOWSKI, A
    NEWMAN, RA
    KRAKOFF, IH
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1985, 26 (MAR): : 152 - 152
  • [46] Preparation of PEG-grafted silica particles using emulsion method
    Oh, C
    Do Ki, C
    Chang, JY
    Oh, SG
    MATERIALS LETTERS, 2005, 59 (8-9) : 929 - 933
  • [47] Preparation and characterization of PEG-grafted silica particles using emulsion
    Hwang, Yi-Jeong
    Lee, Young-Ho
    Oh, Chul
    Jun, Young-Doo
    Oh, Seong-Geun
    JOURNAL OF INDUSTRIAL AND ENGINEERING CHEMISTRY, 2006, 12 (03) : 380 - 386
  • [48] THE NEUROTOXICITY OF L-ASPARAGINASE REVISITED
    WHITE, L
    FISHMAN, LS
    SHORE, NA
    LANDING, BH
    JOURNAL OF PEDIATRICS, 1982, 101 (03): : 484 - 485
  • [49] L-ASPARAGINASE INDUCED COAGULOPATHY
    GRALNICK, HR
    HENRY, PH
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1969, 10 (MAR): : 32 - &
  • [50] EXTRACORPOREAL IMMUNOSUPPRESSION WITH L-ASPARAGINASE
    SAMPSON, D
    EUROPEAN SURGICAL RESEARCH, 1973, 5 : 17 - 17